Synthesis and biological evaluation of small molecule modulators of CDK8/Cyclin C complex with phenylaminoquinoline scaffold

Abstract

Background CDK8/CycC complex has kinase activity towards the carboxyterminal domain of RNA polymerase II, and contributes to the regulation of transcription via association with the mediator complex. Different human malignancies, mainly colorectal and gastric cancers, were produced as a result of overexpression of CDK8/CycC in the mediator complex. Therefore, CDK8/CycC complex represents as a cancer oncogene and it has become a potential target for developing CDK8/CycC modulators. Methods A series of nine 4-phenylaminoquinoline scaffold-based compounds 5a-i was synthesized, and biologically evaluated as potential CDK8/CycC complex inhibitors. Results The scaffold substituent effects on the intrinsic inhibitory activity toward CDK8/CycC complex are addressed trying to present a novel outlook of CDK8/CycC Complex inhibitors with 4-phenylaminoquinoline scaffold in cancer therapy. The secondary benzenesulfonamide analogues proved to be the most potent compounds in suppressing CDK8/CycC enzyme, whereas, their primary benzenesulfonamide analogues showed inferior activity. Moreover, the benzene reversed sulfonamide analogues were totally inactive. Discussion The titled scaffold showed promising inhibitory activity data and there is a crucial role of un/substituted sulfonamido group for CDK8/CycC complex inhibitory activity. Compound 5d showed submicromolar potency against CDK8/CycC (IC50 = 0.639 µM) and it can be used for further investigations and to design another larger library of phenylaminoquinoline scaffold-based analogues in order to establish detailed SARs.

Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights

“…To assess the mechanism of action for the tested compounds as potential EGFR and BRAF inhibitors, all target compounds and Erlotinib were subjected experimentally to the kinase screening protocol according to the previously reported procedure ( Table 1 ).3 35 , 36 3 More details are available in the Supplementary Data .…”

“…The co-crystallized ligands were used to define the binding site for docking and the essential binding modes. 35 , 42 , 43 …”

EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones

“…Cytotoxicity was conducted for all synthesized compounds (C1-C18) to determine their killing power of tumor cells, confirming their anticancer activity (Table 1). The standard cytotoxic Erlotinib was applied as control, and five different cell lines were applied and selected as stated in the Supplementary Materials [31][32][33].…”

A New CDK2 Inhibitor with 3-Hydrazonoindolin-2-One Scaffold Endowed with Anti-Breast Cancer Activity: Design, Synthesis, Biological Evaluation, and In Silico Insights

“…Lastly, NU6300 is the first irreversible CDK2 modulator that can bind covalently to the cysteine residue in the ATP binding site [ 21 , 22 , 23 ]. Different indole and indole isosteres-based compounds were shown to potently inhibit cyclin-dependent kinase 2 (CDK2) activity as part of a G1 cell cycle arrest of human breast cancer cells [ 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. A variety of oxindole scaffold-based compounds was synthesized as potential modulators for CDKs.…”